Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Pneumologie ; 77(1): 21-26, 2023 Jan.
Article in German | MEDLINE | ID: covidwho-2212111

ABSTRACT

There is a variety of drug therapy options for treatment of acute SARS-CoV-2 infections. The updated S3 guideline "Recommendations for inpatient therapy of patients with COVID-19" provides clear recommendations in this regard. Which therapy is best suited for which patient and in which phase of the disease must be decided individually based on risk factors, comorbidities and contraindications. This article provides an overview.


Subject(s)
COVID-19 , Humans , SARS-CoV-2 , Risk Factors , Contraindications
2.
JAMA Netw Open ; 5(11): e2242140, 2022 Nov 01.
Article in English | MEDLINE | ID: covidwho-2116969

ABSTRACT

This cohort study examines the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19.


Subject(s)
COVID-19 , Ritonavir , Humans , Ritonavir/therapeutic use , Prevalence , Contraindications , COVID-19 Drug Treatment
3.
Dtsch Med Wochenschr ; 147(20): 1313-1320, 2022 10.
Article in German | MEDLINE | ID: covidwho-2050603

ABSTRACT

There is a variety of drug therapy options for treatment of acute SARS-CoV-2 infections. The updated S3 guideline "Recommendations for inpatient therapy of patients with COVID-19" provides clear recommendations in this regard. Which therapy is best suited for which patient and in which phase of the disease must be decided individually based on risk factors, comorbidities and contraindications. This article provides an overview.


Subject(s)
COVID-19 Drug Treatment , Contraindications , Humans , Risk Factors , SARS-CoV-2
6.
J Card Surg ; 37(4): 1059-1062, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1642715

ABSTRACT

INTRODUCTION: The coronavirus disease 2019 (COVID-19) causes a small proportion of patients to be admitted to intensive care units, where they sometimes require extracorporeal membrane oxygenation (ECMO). The literature on pregnant women with COVID-19 who require ECMO is sparse. CASE REPORT: We describe here the earliest-fetal-age pregnant patient with COVID-19 who underwent ECMO yet reported, who kept her child while under close follow-up with magnetic resonance imagery and ultrasound. CONCLUSION: The management of acute respiratory distress syndrome (ARDS) in pregnant women, including ARDS secondary to COVID-19 and those cases which are not eligible for fetal delivery, may benefit from the assistance of ECMO even in the early pregnancy.


Subject(s)
COVID-19 , Extracorporeal Membrane Oxygenation , Respiratory Distress Syndrome , COVID-19/complications , COVID-19/therapy , Child , Contraindications , Female , Gestational Age , Humans , Pregnancy , Respiratory Distress Syndrome/diagnostic imaging , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/therapy , SARS-CoV-2
7.
Clin Exp Dermatol ; 47(4): 735-738, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1515201

ABSTRACT

Patients who develop an immediate allergic reaction within the first 4 h of COVID-19 vaccine injection are recommended not to receive the same vaccine again. This recommendation mainly focuses on the mRNA and adenoviral vector COVID-19 vaccines, but data for whole virus vaccines are unknown. We report seven patients who developed an immediate reaction within 4 h (six had generalized urticaria, one had localized urticaria) after the first vaccination with CoronaVac, the inactivated SARS-CoV-2 vaccine. The results of skin tests and basophil activation tests suggested that spike peptides play a role in exacerbating urticaria in some patients. However, all subjects who developed urticaria within 4 h after CoronaVac vaccination were successfully revaccinated without graded challenge, although recurrent urticaria was common. This preliminary result indicates that acute urticaria alone should not be a contraindication for the second dose of CoronaVac if the supply of alternative vaccines is limited.


Subject(s)
COVID-19 , Urticaria , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Contraindications , Humans , Immunization, Secondary , SARS-CoV-2 , Urticaria/etiology , Vaccination/adverse effects
9.
Bull Cancer ; 108(6): 614-626, 2021 Jun.
Article in French | MEDLINE | ID: covidwho-1202973

ABSTRACT

The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at "high risk" for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another "very high-priority" population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.


Subject(s)
COVID-19 Vaccines/administration & dosage , COVID-19/prevention & control , Neoplasms/therapy , COVID-19/epidemiology , COVID-19/immunology , COVID-19 Vaccines/adverse effects , COVID-19 Vaccines/immunology , COVID-19 Vaccines/supply & distribution , Contraindications , France/epidemiology , Humans , Immunotherapy, Adoptive , Molecular Targeted Therapy , Neoplasms/immunology , Pandemics , Vaccination
10.
Int J Infect Dis ; 108: 1-3, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1163872

ABSTRACT

OBJECTIVES: In a conventional hospital ward, we used high-flow nasal oxygen (HFNO) to treat elderly COVID-19 patients noneligible for intensive care unit transfer. METHODS: This study was conducted in the Institut Hospitalo-Universitaire Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille (AP-HM), France. We used high-flow nasal oxygen (HFNO) in our conventional infectious disease ward from 15 September 2020 for elderly patients noneligible for intensive care unit transfer. RESULTS: Of the 44 patients (median age 83 years (57-94), mean: 80.25), 61.4% (27/44) were men. The median Charlson score was 7 (1-15). The median of the NEWS-2 score upon admission was 8 (3-11) and was 10 at the time of initiation of HFNO. The median PaO2/FiO2 ratio was 103 (71-151) prior to HNFO initiation. Among the 44 patients, 16 patients (36.4%) had been weaned from HFNO, and 28 patients had died (63.6%). CONCLUSIONS: In this preliminary report, we observed that HFNO saved the lives of one-third of elderly COVID-19 patients who would have systematically died.


Subject(s)
COVID-19 , RNA, Viral , Aged , Aged, 80 and over , Contraindications , Humans , Intensive Care Units , Male , Oxygen , SARS-CoV-2
12.
J Plast Reconstr Aesthet Surg ; 73(12): 2127-2135, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-1023479

ABSTRACT

Coronavirus disease-2019 (COVID-19) has generated a need to rapidly increase online consulting in secondary care, an area in which it has previously been underutilised. We sought to review the guidance on conducting remote consultations and found that while there is a large amount of information about the implementation of remote consultations at an organisation level, there is a paucity of high-quality papers considering the guidelines for online consultations alongside practical advice for their implementation at the individual level. We reviewed guidelines from reputable medical sources and generated practical advice to assist practitioners to perform safe and effective video consultation. Additionally, we noted reports in the literature of a lack of transparency and resulting confusion regarding the choice of telemedicine platforms. We, therefore, sought to summarise key characteristics of a number of major telemedicine platforms. We recognised a lack of clarity regarding the legal status of performing remote consultations, and reviewed advice from medico-legal sources. Finally, we address the sources of these individual uncertainties, and give recommendations on how these might be addressed systematically, so the practitioners are well trained and competent in the use of online consultations, which will inevitably play an increasingly large role in both primary and secondary care settings in the future.


Subject(s)
COVID-19/epidemiology , Pandemics , Remote Consultation/organization & administration , Contraindications , Hospitalists , Humans , National Health Programs/organization & administration , Practice Guidelines as Topic , Remote Consultation/legislation & jurisprudence , Remote Consultation/methods , SARS-CoV-2 , United Kingdom/epidemiology
13.
BJU Int ; 126(6): 670-678, 2020 12.
Article in English | MEDLINE | ID: covidwho-998799

ABSTRACT

OBJECTIVE: To assess the risk of viral infection during urological surgeries due to the possible hazards in tissue, blood, urine and aerosolised particles generated during surgery, and thus to understand the risks and make recommendations for clinical practice. PATIENTS AND METHODS: We reviewed the available literature on urological and other surgical procedures in patients with virus infections, such as human papillomavirus, human immunodeficiency virus and hepatitis B, and current publications on coronavirus disease 2019 (COVID-19). RESULTS: Several possible pathways for viral transmission appear in the literature. Recently, groups have detected severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the urine and faeces, even after negative pharyngeal swabs. In addition, viral RNA can be detected in the blood and several tissues. During surgery, viral particles are released, aerosol-borne and present a certain risk of transmission and infection. However, there is currently no evidence on the exact risk of infection from the agents mentioned above. It remains unclear whether or not viral particles in the urine, blood or faeces are infectious. CONCLUSIONS: Whether SARS-CoV-2 can be transmitted by aerosols remains controversial. Irrespective of this, standard surgical masks offer inadequate protection from SARS-CoV-2. Full personal protective equipment, including at least filtering facepiece-2 masks and safety goggles should be used. Aerosolised particles might remain for a long time in the operating theatre and contaminate other surfaces, e.g. floors or computer input devices. Therefore, scrupulous hygiene and disinfection of surfaces must be carried out. To prevent aerosolisation during laparoscopic interventions, the pneumoperitoneum should be evacuated with suction devices. The use of virus-proof high-efficiency particulate air filters is recommended. Local separation of anaesthesia/intubation and the operating theatre can reduce the danger of viral transmission. Lumbar anaesthesia should be considered especially in endourology. Based on current knowledge, COVID-19 is not a contraindication for acute urological surgery. However, if possible, as European guideline committees recommend, non-emergency urological interventions should be postponed until negative SARS-CoV-2 tests become available.


Subject(s)
COVID-19/transmission , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Urologic Surgical Procedures/adverse effects , Aerosols , Contraindications , Feces/virology , Filtration , Humans , Infection Control , Laparoscopy/adverse effects , Laparoscopy/methods , Operating Rooms/standards , Personal Protective Equipment , Practice Guidelines as Topic , RNA, Messenger/analysis , Risk Factors , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Urologic Surgical Procedures/methods , Virus Diseases/prevention & control , Virus Diseases/transmission
14.
J Fam Pract ; 69(8): 406;408;411, 2020 10.
Article in English | MEDLINE | ID: covidwho-918748

ABSTRACT

New vaccine and antiviral products are available, and additional vaccine contraindications are identified. The concurrence of influenza and SARS-coV-19 could create synergies for preventive care.


Subject(s)
Antiviral Agents/therapeutic use , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , COVID-19 , Contraindications , Coronavirus Infections , Humans , Immunization Schedule , Influenza Vaccines/adverse effects , Pandemics , Pneumonia, Viral
SELECTION OF CITATIONS
SEARCH DETAIL